Chasserot-Golaz S, Beck G
Institut de Biologie Moléculaire et Cellulaire du CNRS 15, Strasbourg, France.
Cancer Lett. 1988 Aug 30;41(3):333-43. doi: 10.1016/0304-3835(88)90295-9.
The antiproliferative effect of the potent antiglucocorticoid and antiprogestin RU38486, an 11 beta-substituted nor-steroid, was investigated on the HTC cell line. Its action clearly visualized in absence of serum, is reversible. Dexamethasone does whereas progesterone does not protect the cells against the cytostatic effect. Thus, the latter rather depends on the antiglucocorticoid- and not on the antiprogestin-function of RU38486. Taking into account the antiproliferative action on HTC cells together with the antiglucocorticoid behaviour in hepatocytes and hepatomas, our results suggest that RU38486 might represent a potential drug for liver tumour therapy.
强效抗糖皮质激素和抗孕激素RU38486(一种11β-取代的去甲甾体)对HTC细胞系的抗增殖作用进行了研究。其在无血清条件下的作用清晰可见,且是可逆的。地塞米松可起到保护作用,而孕酮则不能保护细胞免受细胞生长抑制作用。因此,后者更依赖于RU38486的抗糖皮质激素功能而非抗孕激素功能。综合考虑其对HTC细胞的抗增殖作用以及在肝细胞和肝癌中的抗糖皮质激素行为,我们的结果表明RU38486可能是一种潜在的肝脏肿瘤治疗药物。